Groundbreaking research and clinical trials led by CCR’s Pediatric Oncology Branch resulted in FDA approval of the drug selumetinib, which shrinks tumors and improves quality of life in children living with neurofibromatosis type 1 (NF1). CAR T-cells are being used to target new tumor markers in children and young adults with acute leukemias and lymphomas. CCR researchers are also working to find new therapeutic targets for other rare childhood cancers such as neuroblastomas, synovial sarcoma and rhabdomyosarcoma. We invite you to meet some of our principal investigators conducting research on these diseases.
